CMPS - COMPASS Pathways: Risky But Can Pay Back Generously
- COMPASS Pathways is a biotech psychedelic medicine development and therapy company that has developed a synthetic formulation of psilocybin, COMP360, for combatting treatment-resistant depression.
- Received the highly-valuable FDA Breakthrough Therapy Designation for COMP360 trials and is currently in Phase 2a trials.
- Extensive clinical trial pipeline with 21 sites in 10 countries and partners, including King's College London, Stanford University, and more.
- Backed by PayPal co-founder Peter Thiel, ATAI Life Sciences, and arguably the top biotech investor, Joseph Edelman at Perceptive Advisors.
- COMPASS has quite a few hurdles for keeping the king-of-the-hill designation of public psychedelic companies in the long-term.
For further details see:
COMPASS Pathways: Risky But Can Pay Back Generously